Punit Kumar Rasara
Chairman and Managing Director
Notable Quotes
We are believing that result would be much better than 370 to 380 CR.
We are the only Indian manufacturer of loxoprofen and we'll have the first-mover advantage with monopoly in pain management.
In healthcare segment all the pharma company in India are almost at the same level... everyone is having equal opportunities.